Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

Status:	Archived
Conditions:	Pulmonary
Therapuetic Areas:	Pulmonary / Respiratory Diseases
Healthy:	No
Age Range:	Any
Updated:	7/1/2011
Start Date:	May 2009
End Date:	December 2010

Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)

This Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled, single
followed by multiple dose, dose escalation study designed to evaluate the safety,
tolerability, pharmacokinetics, immunogenicity, and impact of STX-100 on gene and protein
expression for Î±vÎ²6 related and TGF-Î²-inducible genes (including tubulointerstitial injury,
epithelial function, and IF/TA related genes) in renal transplant patients with biopsy.

We found this trial at

site

Stromedix Investigative Site

Cambridge, Massachusetts 02141

from

Cambridge, MA

Study of STX-100 in Renal Transplant Patients With Interstitial Fibrosis and Tubular Atrophy (IF/TA)

Use our guide to learn which trials are right for you!

Randomized Double-Blind, Placebo-Controlled, Single and Multiple Dose, Dose-Escalation Study of STX 100 in Renal Transplant Patients With Biopsy Proven Interstitial Fibrosis and Tubular Atrophy (IF/TA)

Select your condition

Common Conditions

All Conditions